AGO TUMOR - AN OVERVIEW

If lymph node involvement is proven in a client going through neoadjuvant therapy that is a possible prospect for targeted axillary dissection (TAD), a marker must be inserted during the lymph node following biopsy.In a very new randomized controlled trial, MRI in the extremely dense breast screening team with destructive MG confirmed a significant